SDC1 and neoplasm: Using the tumor-targeted SDC1-Lip as a delivery vehicle for echinomycin treatment (1nM and 10nM), cell viability was significantly reduced under normoxic conditions of S2VP10 (p = 0.001, p < 0.00001) and S2CP9 (p = 0.001, p < 0.00001) compared to treatment with echinomycin only (Figure 2A).